IPR decision (Feb. 21, 2018):
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
Patent No.
|
Status
|
|
IPR2016-01614
|
08/15/2016
|
Celltrion, Inc.
|
Apotex Inc.
|
US 7,820,161
|
claims 1–12 are patentable
|
On US’161 patent, Celltrion previously filed IPR (IPR2015-01744) which was denied. Boehringer Ingelheim filed IPR (IPR2015-00415) which was terminated (Oct 2015) as BI filed “Request for Adverse Judgment”. Pfizer also filed IPR (IPR2017-01115) on 03/24/2017 which was instituted on 07/18/2017.
US 7,820,161 (Genentech / Biogen; Exp: May 04, 2020)
1. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab; and (b) administering to the human methotrexate.
5. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of an antibody that binds to the CD20 antigen on human B lymphocytes; and (b) administering to the human methotrexate; wherein the CD20 antibody administration consists of intravenous administration of the CD20 antibody, and the CD20 antibody is rituximab.
9. A method of treating rheumatoid arthritis in a human comprising: (a) administering to the human more than one intravenous dose of a therapeutically effective amount of an antibody that binds to the CD20 antigen on human B lymphocytes; and (b) administering to the human methotrexate; wherein the therapeutically effective amount of the CD20 antibody is administered intravenously, and the CD20 antibody is rituximab.
Leave a Reply